Gain Therapeutics Inc. (GANX)
Gain Therapeutics Statistics
Share Statistics
Gain Therapeutics has 27.79M shares outstanding. The number of shares has increased by 46.94% in one year.
| Shares Outstanding | 27.79M |
| Shares Change (YoY) | 46.94% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 7.48% |
| Shares Floating | 26.42M |
| Failed to Deliver (FTD) Shares | 1.5K |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 658.34K, so 2.48% of the outstanding shares have been sold short.
| Short Interest | 658.34K |
| Short % of Shares Out | 2.48% |
| Short % of Float | 2.61% |
| Short Ratio (days to cover) | 1.65 |
Valuation Ratios
The PE ratio is -2.42 and the forward PE ratio is -2.65. Gain Therapeutics's PEG ratio is 0.05.
| PE Ratio | -2.42 |
| Forward PE | -2.65 |
| PS Ratio | 0 |
| Forward PS | 2.3 |
| PB Ratio | 6.73 |
| P/FCF Ratio | -2.62 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Gain Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.97 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-887.44K |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 536.82K |
| Effective Tax Rate | -2.7% |
Stock Price Statistics
The stock price has increased by -50% in the last 52 weeks. The beta is 0.19, so Gain Therapeutics's price volatility has been higher than the market average.
| Beta | 0.19 |
| 52-Week Price Change | -50% |
| 50-Day Moving Average | 2.18 |
| 200-Day Moving Average | 1.8 |
| Relative Strength Index (RSI) | 38.37 |
| Average Volume (20 Days) | 231.88K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -20.35M |
| Net Income | -20.41M |
| EBITDA | -20.35M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.89 |
Balance Sheet
The company has 10.39M in cash and 214.51K in debt, giving a net cash position of 10.17M.
| Cash & Cash Equivalents | 10.39M |
| Total Debt | 214.51K |
| Net Cash | 10.17M |
| Retained Earnings | -60.78M |
| Total Assets | 12.12M |
| Working Capital | 7.69M |
Cash Flow
In the last 12 months, operating cash flow was -18.87M and capital expenditures -22.49K, giving a free cash flow of -18.9M.
| Operating Cash Flow | -18.87M |
| Capital Expenditures | -22.49K |
| Free Cash Flow | -18.9M |
| FCF Per Share | -0.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for GANX is $7.5, which is 319% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.5 |
| Price Target Difference | 319% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -8.14 |
| Piotroski F-Score | 3 |